4-(piperidin-4-ylsulfonyl)benzonitrile | 1450723-99-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(piperidin-4-ylsulfonyl)benzonitrile
• 英文别名: 4-Piperidin-4-ylsulfonylbenzonitrile
• CAS: 1450723-99-5
• 化学式: C₁₂H₁₄N₂O₂S
• 分子量: 250.321
• InChiKey: SLRRGIQZWBIWAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  78.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(piperidin-4-ylsulfonyl)benzonitrile 在 氨 、 氢气 、 sodium cyanoborohydride 作用下， 以 甲醇 、 乙醇 、 溶剂黄146 为溶剂， 反应 13.0h， 生成 (4-((1-Isopropylpiperidin-4-yl)sulfonyl)phenyl)methanamine
  参考文献：
  名称：

  Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)

  摘要：

  Potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors containing 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas were identified using structure-based design techniques. The new compounds displayed improved aqueous solubilities, determined using a high-throughput solubility assessment, relative to previously disclosed urea and amide-containing NAMPT inhibitors. An optimized 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived compound exhibited potent anti-NAMPT activity (18; BC NAMPT IC50 = 11 nM; PC-3 antiproliferative IC50 = 36 nM), satisfactory mouse PK properties, and was efficacious in a PC-3 mouse xenograft model. The crystal structure of another optimized compound (29; NAMPT IC50 = 10 nM; A2780 antiproliferative IC50 = 7 nM) in complex with the NAMPT protein was also determined. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.090
• 作为产物：
  描述：

  4-(4-氰基苯磺酰基)-哌啶-1-羧酸叔丁酯 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 以83%的产率得到4-(piperidin-4-ylsulfonyl)benzonitrile
  参考文献：
  名称：

  Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)

  摘要：

  Potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors containing 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas were identified using structure-based design techniques. The new compounds displayed improved aqueous solubilities, determined using a high-throughput solubility assessment, relative to previously disclosed urea and amide-containing NAMPT inhibitors. An optimized 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived compound exhibited potent anti-NAMPT activity (18; BC NAMPT IC50 = 11 nM; PC-3 antiproliferative IC50 = 36 nM), satisfactory mouse PK properties, and was efficacious in a PC-3 mouse xenograft model. The crystal structure of another optimized compound (29; NAMPT IC50 = 10 nM; A2780 antiproliferative IC50 = 7 nM) in complex with the NAMPT protein was also determined. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.090

文献信息

• [EN] 4-ARYLSULPHONYLPIPERIDINE DERIVATIVES FOR ANTAGONISM OF THE 5-HT2A RECEPTOR<br/>[FR] DERIVES DE 4-ARYLSULPHONYLPIPERIDINE POUR L'ANTAGONISME DU RECEPTEUR DE 5-HT2A
  申请人：MERCK SHARP & DOHME

  公开号：WO2004101518A1

  公开（公告）日：2004-11-25

  Compounds of formula (I): are selective antagonists of the 5-HT2A receptor, and hence are useful in treatment of adverse conditions at the central nervous system, such as sleep disorders and schizophrenia.

  式(I)的化合物是5-HT2A受体的选择性拮抗剂，因此在治疗中枢神经系统的不良症状，如睡眠障碍和精神分裂症方面具有用处。
• 4-Arylsulphonylpiperidine derivatives for antagonism of the 5-ht2a receptor
  申请人：Gilligan Myra

  公开号：US20060211735A1

  公开（公告）日：2006-09-21

  Compounds of formula (I): are selective antagonists of the 5-HT 2A receptor, and hence are useful in treatment of adverse conditions at the central nervous system, such as sleep disorders and schizophrenia.

  公式为(I)的化合物是5-HT2A受体的选择性拮抗剂，因此可用于治疗中枢神经系统的不良症状，如睡眠障碍和精神分裂症。
• 4-ARYLSULPHONYLPIPERIDINE DERIVATIVES FOR ANTAGONISM OF THE 5-HT2A RECEPTOR
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP1641756A1

  公开（公告）日：2006-04-05
• PROTEOLYSIS-TARGETING CHIMERA (PROTAC) COMPOUNDS AND USES THEREOF FIELD
  申请人：[en]AUBRAK THERAPEUTICS

  公开号：WO2024165050A1

  公开（公告）日：2024-08-15

  The present disclosure relates generally to PROTAC (proteolysis-targeting chimera) compounds, pharmaceutical compositions comprising such compounds, and methods of treating various diseases and conditions with such compounds.